Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi Genzyme's Sibold On Investing In Blood Disorders And Fending Off Rivals

Executive Summary

Sibold talked to Scrip about launching the blood clotting disorder drug Cablivi and finding room in a competitive hemophilia market.

You may also be interested in...



Enjaymo Marks Latest Milestone In Sanofi’s Blood Disorder Effort

The company plans to draw on experience with other rare blood disorder drug launches, but pointed to some differences in the market for cold agglutinin disease.

New Sanofi CEO's Big Priority Is Bolstering R&D

In CEO Paul Hudson's first earnings call at the company's helm, he said he has big goals for driving growth but a deeper strategic update will be outlined to investors on Dec. 10 in Cambridge, Mass.

Sanofi Prioritizes Cancer And Rare Diseases In Pipeline Shake-Up

Hours after getting the nod from the FDA for Cablivi, the French drugmaker has had an R&D pipeline overhaul and says it could potentially submit nine new medicines and 25 additional indications to regulatory authorities from 2019 to 2022.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC125282

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel